Spots Global Cancer Trial Database for Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Official Title: A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies

Study ID: NCT02538510

Conditions

Head and Neck Squamous Cell Carcinoma

Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma

Recurrent Nasopharynx Carcinoma

Recurrent Salivary Gland Carcinoma

Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary

Stage III Major Salivary Gland Carcinoma

Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma

Stage III Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma

Stage IVA Major Salivary Gland Carcinoma

Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma

Stage IVB Major Salivary Gland Carcinoma

Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma

Stage IVC Major Salivary Gland Carcinoma

Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma

Interventions

Laboratory Biomarker Analysis

Pembrolizumab

Vorinostat

Study Description

Brief Summary: This phase I/II trial studies the side effects of pembrolizumab and vorinostat in treating patients with squamous cell head and neck cancer or salivary gland cancer that has come back, has spread to other places in the body and/or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab together with vorinostat may be a better treatment for head and neck cancer or salivary gland cancer.

Detailed Description: OUTLINE: Patients receive vorinostat orally (PO) once daily (QD) or via percutaneous endoscopic gastrostomy (PEG) on days 1-5 and pembrolizumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and every 8-12 weeks thereafter.